For more information about products within the Pathway Portfolio, please click here for prescribing information
CNS Range
The Pathway Portfolio is Aspire Pharma’s branded generic portfolio with products covering a wide range of therapy areas, including: CNS, Respiratory, Cardiovascular, Pain and Urology.
Each product in the portfolio has its own key offerings, ranging from:
- A full range of strengths available1
- A first strength to market1
- Simpler dosing which may help some patients with concordance and compliance1-2
- The first brand to market1
All of which create a wider offering to patients.
Pathway to Partnership:
Trusted Brands:
- Bioequivalent to brand originators3
- Available from mainline wholesalers
Bespoke Support:
- Price guarantee
- Individualised rebates on request
Assicco® (glycopyrronium bromide) tablets
Indicated for the symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders.4
Assicco® is the only available brand of glycopyrronium bromide tablets1.
Assicco® could reduce the average ICS/ICB prescribing costs of glycopyrronium bromide tablets by an average of £7,254 per annum, saving up to £261,143 annually across the NHS5*.
Biquelle XL® (quetiapine)
prolonged-release tablets
Indicated for schizophrenia; moderate to severe manic and major depressive episodes in bipolar disorder; prevention of recurrence of manic or depressed episodes in bipolar patients who have previously responded to quetiapine treatment; add-on treatment of major depressive episodes in patients with major depressive disorder (MDD) who have had sub-optimal response to antidepressant monotherapy6.
Biquelle® XL: the most complete range of quetiapine prolonged-released tablets, with a 600mg strength available1.
(Biquelle XL 600mg dose, is only available as a 30 day pack.)‡
Gatalin® XL (galantamine)
prolonged-release capsules
Indicated for symptomatic treatment of mild to moderately severe dementia of the Alzheimer type7.
Save 50% compared to tariff galantamine prolonged-release prescribing costs by prescribing Gatalin® XL by brand1.
Repinex XL® (ropinirole)
prolonged-release tablets
Indicated for initial treatment in adults of Parkinson’s disease as a monotherapy to delay the introduction of levodopa or in combination with levodopa, over the course of the disease, when levodopa effect wears off or becomes inconsistent and fluctuations in therapeutic effect occur8.
Save 50% compared to drug tariff ropinirole prolonged-release prescribing costs by prescribing Repinex XL by brand1.
Vencarm® XL (venlafaxine)
prolonged-release tablets
All strengths: Major depressive episodes (MDEs), prevention of recurrence of MDEs. 37.5, 75, 150 and 225mg: generalised anxiety disorder (GAD), social anxiety disorder (SAD) and panic disorder, with or without agoraphobia9.
Prescribing Vencarm® XL by brand remains the most cost-effective range of venlafaxine prolonged release capsules1.
Vencarm® XL could reduce the average ICS/ICB prescribing costs of venlafaxine prolonged release capsules by an average of £357,143 per annum, saving up to £15 million annually across the NHS5*.
References:
*Average ICS is based on 4 x Moving Quarterly Turnover (MQT) divided by 36 ICS/ICB’s
- UK Drug Tariff (Accessed June 2026)
- Kyoko Higashiet al. Dosing frequency and adherence in chronic psychiatric disease: systematic review and meta-analysis. Neuropsychiatric Disease and Treatment, 2013; 9: 119–131 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3552550/
- REF-00061-1 | Bioequivalence Data on File
- Assicco® SmPC (Accessed June 2026)
- MAT-UK-EPI-0139-1 Pathway Portfolio cost savings, GPPLPD Date Range: Jan-26 – Mar-26
- Biquelle® XL SmPC (Accessed June 2026)
- Gatalin® XL SmPC (Accessed June 2026)
- Repinex® XL SmPC (Accessed June 2026)
- Vencarm® XL SmPC (Accessed June 2026)
MAT-UK-XLP-0031-1 | June 2026
